LOAN MODIFICATION AGREEMENT NO. 1

     Preamble: This Loan Modification Agreement No. 1 (this "Agreement"),  dated
as of September 11, 2001 (the "Effective Date"), is made between IMMUCOR,  INC.,
a Georgia  corporation ("U.S.  Borrower"),  DOMINION  BIOLOGICALS  LIMITED,  the
successor  by   amalgamation  to  3000524  Nova  Scotia  Limited  and  itself  a
corporation  incorporated  under the laws of Canada ("Canadian  Borrower"),  and
IMMUCOR MEDIZINISCHE DIAGNOSTIK GMBH, a corporation  incorporated under the laws
of the Federal Republic of Germany ("German Borrower";  U.S. Borrower,  Canadian
Borrower and German Borrower,  individually and  collectively,  "Borrower"),  as
borrowers,   and  WACHOVIA  BANK,  NATIONAL  ASSOCIATION,   a  national  banking
association,  as lender  ("Lender")  for the purpose of  amending  or  otherwise
modifying  the terms of that  certain Loan  Agreement,  dated as of February 23,
2001,  heretofore  made between Lender and Borrower  (which,  as it has been, or
hereafter may be, modified or amended, is called herein the "Loan Agreement").

     Now,  therefore,  in consideration of the mutual promises  contained herein
and in the Loan  Agreement,  the  receipt  and  sufficiency  of which are hereby
acknowledged,  Lender and Borrower, each intending to be legally bound, agree as
follows:

1.  Definitions.  Capitalized  terms  used  herein,  but not  expressly  defined
themselves  herein,  shall  have the  meanings  given to such  terms in the Loan
Agreement.

2. Loan Modifications. Lender and Borrower agree to modify the Loan Agreement as
follows:

2.1 Change in Interest Rate and Non-Usage Fee. Notwithstanding any provisions of
Sections 2.2.1 or 2.2.2 of the Loan Agreement to the contrary, commencing on the
Effective Date:

(i)  all  Borrowings  shall be limited to, and made as (or converted  to), Prime
     Borrowings only;

(ii) the  "Applicable  Margin" shall be a rate per annum equal to (A) in respect
     of Advances  outstanding under each of the Lines of Credit, Term Loan A and
     CAD Term Loan, one-half of one percent (0.50%),  and (B) in respect of Term
     Loan B, two percent (2.00%); and

(iii)the  "Applicable  Percentage"  for the  non-usage  fee  shall  be  fixed at
     one-half of one percent (0.50%);

provided, however, that if the Funded Debt/EBITDA Ratio of the U.S. Borrower and
its Consolidated Subsidiaries (computed as of the last day of any Fiscal Quarter
ending  subsequent to the  Effective  Date for the four (4)  consecutive  Fiscal
Quarters ending on such date), as reflected on Borrower's  financial  statements
for such Fiscal  Quarter (and the three (3) preceding  Fiscal  Quarters) is ever
2.50:1 or less, then, so long as such situation,  measured quarterly thereafter,
is  continuing,  the  foregoing  provisions of clauses (i), (ii) and (iii) above
shall be suspended  and the  existing  provisions  of Sections  2.2.1 and 2.2.2,
relative to selection and  calculation  of interest  rates and of calculation of
non-usage fees, shall be reinstated.
<PAGE>

2.2 Change in Borrowing Base Reporting. Notwithstanding any provision of Section
4.2.10 of the Loan Agreement to the contrary,  commencing with the calendar week
ending September 24, 2001, and continuing at all times thereafter, the Borrowing
Base  Certificate  shall be delivered on a weekly basis,  as soon as practicable
after the end of each calendar week, but not later than the second  Business Day
of the succeeding  calendar week,  reflecting  weekly updates of the information
specified in said Section 4.2.10 for the U.S. Borrower and its Subsidiaries, and
monthly  updates of such  information  for the German  Borrower and the Canadian
Borrower. In addition to the foregoing, Borrower shall provide Lender with (i) a
Borrowing Base  Certificate  for the calendar month ended July 31, 2001, as soon
as  practicable  hereafter,  but not later than  September  24,  2001,  and (ii)
Borrowing Base Certificates for (A) the calendar month ended August 31, 2001 and
(B) the  three-week  period ended  September  21, 2001,  as soon as  practicable
hereafter,  but not later than September 28, 2001. In such regard, Lender waives
the Events of Default  heretofore  existing in respect of Borrower's  failure to
deliver  Borrowing Base Certificates for the calendar months ended July 31, 2001
and August 31, 2001 in a timely manner on the condition,  however, that Borrower
will make the deliveries set forth herein by not later than the dates  specified
hereinabove or else such Events of Default shall be reinstated.

2.3 Changes in Financial Covenants.  Any Event of Default heretofore existing in
respect of Borrower's non-compliance with any of Sections 6.1 through 6.4 of the
Loan Agreement for the Fiscal Quarters ending February 28, 2001 and May 31, 2001
(but only for such Fiscal  Quarters,  and no other  Fiscal  Quarter,  including,
particularly  the Fiscal  Quarter  ending  August 31,  2001) are hereby  waived,
effective as of the Effective Date, and, in connection therewith, (i) compliance
with  Sections 6.1, 6.3 and 6.4 of the Loan  Agreement is suspended  through the
Fiscal  Quarter  ending  February 28, 2002,  but shall be  reinstated  as of the
Fiscal Quarter ending May 31, 2002, (ii) Section 6.2 of the Loan Agreement shall
be amended and restated to read as set forth below:

6.2  Funded   Debt/EBITDA   Ratio.  The  U.S.   Borrower  and  its  Consolidated
Subsidiaries  shall have for each Fiscal Quarter ending closest to each date set
forth below a Funded Debt/EBITDA Ratio of not more than that set forth below for
such period:
<PAGE>

                                                   Maximum Funded
     Fiscal Quarter Ending:                       Debt/EBITDA Ratio:

     August 31, 2001                                 5.90:1.00

     November 30, 2001                               4.50:1.00

     February 28, 2002                               3.65:1.00

     May 31, 2002                                    2.70:1.00

     Each Fiscal Quarter ending                      2.50:1.00
     after May 31, 2002

Solely for  purposes of this  Section  6.2,  (i) so long as any Debt of the U.S.
Borrower or any of its  Consolidated  Subsidiaries  is, by its terms,  expressly
subordinated  to the  obligations  of such  Credit  Party to Lender,  including,
without  limitation,  all Obligations,  on terms and conditions  satisfactory to
Lender in its sole  discretion,  and so long as Lender  determines,  in its sole
discretion, that such subordination is and continues to be in all respects valid
and enforceable against the holders of such obligations,  such subordinated Debt
shall not be included as Funded  Debt;  provided,  however,  that the  foregoing
shall not be deemed to be a consent  by Lender to the  incurrence  by any Credit
Party of any Debt not  otherwise  permitted  to be incurred  pursuant to Section
5.2; and (ii)  commencing  with the Fiscal  Quarter ending closest to August 31,
2001, and  continuing  through the Fiscal Quarter ending closest to February 28,
2002, EBITDA shall be computed on an "annualized"  basis; that is, (A) EBITDA at
the end of the Fiscal  Quarter  ending closest to August 31, 2001 shall be equal
to EBITDA determined for such Fiscal Quarter  multiplied by four (4), (B) EBITDA
at the end of the Fiscal  Quarter  ending  closest to November 30, 2001 shall be
equal to EBITDA for the two (2)  consecutive  Fiscal  Quarters  ending with such
Fiscal  Quarter  end,  multiplied  by two (2),  and (C) EBITDA at the end of the
Fiscal Quarter ending closest to February 28, 2002, shall be equal to EBITDA for
the three (3)  consecutive  Fiscal Quarters ending with such Fiscal Quarter end,
multiplied by four-thirds (4/3).

and (ii),  there  shall be added to  Article  6 a new  Section  6.5,  to read as
follows:

     6.5 Minimum EBITDA.  The U.S.  Borrower and its  Consolidated  Subsidiaries
shall have for each Fiscal  Quarter  ending closest to each date set forth below
and for the  cumulative  Fiscal Year to date a minimum  EBITDA in the respective
amounts set forth below corresponding thereto:
<PAGE>

                                                          Minimum Fiscal
   Fiscal Quarter              Minimum                    Year-to-Date
   Ending                      Quarterly EBITDA           EBITDA

   August 31, 2001             $2,000,000                 $2,000,000

   November 30, 2001           $3,000,000                 $5,000,000

   February 28, 2002           $4,000,000                 $9,000,000

   May 31, 2002                $5,000,000                 $14,000,000

it being understood and agreed, in connection herewith,  for the Fiscal Quarters
ending  November  30, 2001,  February 28, 2002 and May 31, 2002,  that if actual
quarterly EBITDA is less than the minimum  quarterly EBITDA prescribed above for
such Fiscal Quarter,  such shortfall shall not by itself  constitute an Event of
Default  unless  either (i) actual  EBITDA is less than eighty  percent (80%) of
prescribed  EBITDA for such Fiscal Quarter or (ii) Borrower is in non-compliance
with the minimum  Fiscal  Year-to-date  EBITDA  requirement  prescribed for such
Fiscal Quarter.

2.4  Unsatisfied  Post-Closing  Conditions.  Pursuant to Section 4.8 of the Loan
Agreement, Borrower was required to deliver, or cause to be delivered, to Lender
by not later than April 30, 2001, certain Loan Documents.  As of April 30, 2001,
and  continuing  through the Effective  Date, the Borrower has failed to deliver
those Loan  Documents  listed on  Schedule  "A" annexed  hereto (the  "Remaining
Post-Closing  Conditions"),  and its failure to do has  constituted  an Event of
Default since April 30, 2001 (herein,  the "Document Delivery  Default").  As an
accommodation to Borrower, Lender hereby waives the Document Delivery Default on
the  condition,  however  (to  which the  Borrower  acknowledges,  confirms  and
agrees),  that, as soon as practicable  hereafter,  but not later than September
30, 2001, Borrower shall have fulfilled all Remaining  Post-Closing  Conditions;
otherwise,  effective on October 1, 2001, the Document Delivery Default shall be
reinstated.

3.  Imposition  of Waiver Fee.  In  consideration  of  Lender's  entry into this
Agreement and its performance  hereunder,  Lender shall have fully earned on the
Effective  Date a  non-refundable  waiver  fee equal in amount to Seven  Hundred
Fifty Thousand Dollars ($750,000),  the payment of which shall be made in twelve
(12), equal  installments of Sixty-Two  Thousand Five Hundred Dollars  ($62,500)
each, due and payable on the last day of each calendar  month,  for twelve (12),
consecutive  calendar  months,  commencing  on  September  30,  2001;  provided,
however, that, notwithstanding the foregoing, the then unpaid amount of such fee
shall become due and payable, in full, (i) upon Borrower's receipt of the Junior
Capital Infusion  (defined and described in Section 4 of this  Agreement),  (ii)
upon any Event of Default  occurring  subsequent to the  Effective  Date, at any
time during its  continuation,  at Lender's  option (but  automatically,  if the
Event of Default is in respect of Sections 7.6 or 7.7 of the Loan  Agreement) or
(iii) upon any termination of the Loan Agreement  occurring in conjunction  with
Borrower's prepayment in full of the Obligations.
<PAGE>

4. Junior Capital  Infusion.  Lender has agreed to enter into this Agreement and
perform hereunder on the condition (which Borrower hereby acknowledges, confirms
and agrees) that, as soon as practicable  hereafter,  but not later in any event
than December 31, 2001 (the "Deadline  Date"),  the Borrower shall have received
cash in the  minimum  amount  of Five  Million  Dollars  ($5,000,000)  (gross of
underwriting  commissions and related expenses) in the form of (A) equity or (B)
Debt which by its  express  terms is  subordinated  to all  Obligations  of each
Credit Party to Lender on terms  satisfactory to Lender,  in its sole discretion
(such capital  infusion,  of either form,  is herein called the "Junior  Capital
Infusion"),  the proceeds from which shall be applied, as and when received,  in
the form  received,  to  outstanding  Obligations  in such  order and  manner as
Lender, in its sole discretion, shall elect; and, if the required Junior Capital
Infusion is not made,  received  and  applied as  specified  hereinabove  by the
Deadline Date, then, the following additional terms shall apply:

(i)  Lender  shall  have  fully  earned  on the  Deadline  Date a  nonrefundable
     supplemental  waiver fee,  equal in amount to Four Hundred  Fifty  Thousand
     Dollars  ($450,000),  separate  and  apart  from  the  initial  waiver  fee
     specified  in Section 3 of this  Agreement,  the  payment of which shall be
     made in twelve (12),  equal  installments  of  Thirty-Seven  Thousand  Five
     Hundred  Dollars  ($37,500)  each,  due and payable on the last day of each
     calendar month for twelve (12) consecutive  calendar months,  commencing on
     January 31, 2002; provided,  however, that,  notwithstanding the foregoing,
     the then unpaid  amount of such fee shall become due and payable,  in full,
     on the same  basis,  at the same  time  and on the same  conditions  as are
     prescribed for the initial waiver fee in Section 3 of this Agreement.

(ii) Lender shall have fully  earned on the  Deadline  Date the right to receive
     directly or through Lender's designee, on such date, warrants ("Warrants"),
     to acquire from the U.S.  Borrower  750,000  shares of voting  common stock
     (or, in lieu thereof, in whole or in part, at Lender's election,  "phantom"
     stock warrants or capital  appreciation rights representing the equivalent,
     in rights and value, thereof), or whatever greater or lesser number of such
     shares which,  upon issuance of the Warrants,  would provide  Lender,  on a
     fully diluted  basis,  the same  percentage  amount of the U.S.  Borrower's
     voting common stock (or alternative  equity rights) as Lender would have on
     the Effective  Date, if the Warrants were issued on such date,  exercisable
     at the then  current  market  price of such stock upon the exercise of such
     Warrants,  with such  Warrants  to be (A)  issued  to Lender  for a nominal
     consideration  only and (B) to be in a form and substance  satisfactory  to
     Lender,   in   its   sole,   but   commercially   reasonable,   discretion.
     Notwithstanding  the  preceding  sentence,  the U.S.  Borrower will have no
     obligation  to  increase  the number of warrants or number of shares of its
     common stock (or alternative  equity rights) issuable upon exercise of such
     warrants as a result of (A) the issuance of its common stock or  securities
     convertible  into its common stock that arise from  employee  stock options
     issued in the ordinary  course of business,  prior to the issuance  date of
     the warrant, or (B) except as expressly provided in the Warrant,  after the
     Warrant has been issued.  The Warrants shall not be exercisable until April
     30,  2002,  however,  nor after five (5) years from their date of issuance,
     and shall be  subject  to  return  to  Borrower,  without  charge,  should,
     subsequent  to the  Deadline  Date and prior to April 1,  2002,  the Junior
     Capital  Infusion  has  been  made,   received  and  applied  as  specified
     hereinabove, according to the following schedule:


  ------------------------------- ---------------------------------------------
  If Junior Capital Infusion is   Then, the Warrants to be returned to
  made, received and applied by:  Borrower shall equal the number of shares
                                  specified below (or their equivalent if
                                  more or less than 750,000 shares are
                                  available by Warrants)
  ------------------------------- ---------------------------------------------

  January 31, 2002                                  562,500
  ------------------------------- ---------------------------------------------

  February 28, 2002                                 375,000
  ------------------------------- ---------------------------------------------

  May 30, 2002                                      187,500
  ------------------------------- ---------------------------------------------


(iii)on the Deadline  Date,  the interest rate payable on Advances  shall change
     to (A) the Prime  Rate plus two  percent  (2%) per  annum,  for each of the
     Lines of Credit, Term Loan A and CAD Term Loan, and (B) the Prime Rate plus
     four percent (4%) per annum, for Term Loan B.

(iv) subsequent  to the Deadline  Date,  unless the Junior  Capital  Infusion is
     made,  received  and applied as  specified  hereinabove  by April 30, 2002,
     then, all existing credit  facilities shall terminate on February 28, 2003,
     and all Obligations  shall be due and payable in full on such date (subject
     to earlier  acceleration in accordance with the terms of the Loan Agreement
     in regard thereto).

5. Weekly Forecasts.  In furtherance of Section 4.2.11 of the Loan Agreement, as
soon as  practicable  hereafter,  by not later than September 28, 2001, the U.S.
Borrower shall provide Lender with thirteen (13) week cash flow  projections for
the U.S.  Borrower and its  Subsidiaries,  which the U.S.  Borrower shall update
(roll forward and reconcile) on a weekly basis thereafter by the second Business
Day of each calendar week for the preceding calendar week.

6. U.S. Virgin Islands  Subsidiary.  U.S. Borrower covenants and agrees to cause
the  dissolution of Gamma  Biologicals  International,  Inc. and to transfer all
assets of such entity, if any, to the U.S.  Borrower.  Upon such dissolution and
transfer,  Gamma  Biologicals  International,  Inc.  shall no longer be a Credit
Party.
<PAGE>

7.  Inducing  Representations.  To induce  Lender to enter into this  Agreement,
Borrower hereby represents and warrants that: (i) Borrower is duly authorized to
enter into this Agreement,  and this  Agreement,  upon its execution by Borrower
and Lender,  will constitute  Borrower's  legal,  valid and binding  obligations
enforceable  in accordance  with its terms against  Borrower;  (ii) after giving
effect to this Agreement,  no Event of Default exists; (iii) no present right of
setoff, counterclaim, recoupment claim, claim, cause or action or defense exists
in Borrower's  favor in respect of its payment or performance of any Obligations
or arising from any action (or inaction) of Lender;  and (iv) except as modified
by this Agreement, all terms of the Loan Agreement and each Loan Document are in
full force and effect as originally stated.

8.   Miscellaneous.   Except  as  otherwise   expressly   provided  herein,  all
modifications  to the Loan  Agreement  set forth herein shall take effect on the
Effective Date. Each existing Loan Document (including,  particularly, any Note)
shall be deemed  modified  hereby as necessary to conform its terms to the terms
of the Loan Agreement,  as modified  hereby.  This Agreement  constitutes a Loan
Document,  and shall be  governed  and  construed  accordingly.  This  Agreement
constitutes  the entire  agreement  between Lender and Borrower  relative to the
subject matter hereof, and supersedes and replaces any prior  understandings and
agreements,  written or oral, in regard thereto. This Amendment shall be binding
on, and inure to the benefit  of, the  successors  and  assigns of Borrower  and
Lender.  Borrower  shall  reimburse  Lender for all costs which  Lender  incurs,
including reasonable attorneys fees, in the preparation,  negotiation, execution
and  performance of this  Agreement,  and the recording of any Loan Documents in
connection herewith.
<PAGE>


     IN WITNESS  WHEREOF,  the parties  hereto have caused this  Agreement to be
executed as of the day and year first above written.

                                             WACHOVIA BANK,
                                             NATIONAL ASSOCIATION


                                             By:
                                             Name:
                                             Title:



































                    [SIGNATURES CONTINUED ON FOLLOWING PAGE)
<PAGE>

                                         IMMUCOR, INC.


                                         By:
                                         Name:  Steven C. Ramsey
                                         Title:    Chief Financial Officer


































                    [SIGNATURES CONTINUED ON FOLLOWING PAGE)
<PAGE>

                                        DOMINION BIOLOGICALS LIMITED


                                        By:
                                            Name:  Steven C. Ramsey
                                            Title:    Vice President




































                    [SIGNATURES CONTINUED ON FOLLOWING PAGE)
<PAGE>

                                       IMMUCOR MEDIZINISCHE DIAGNOSTIK GMBH


                                       By:
                                           Name:  Edward L. Gallup
                                           Title:    Managing Director




<PAGE>


              WACHOVIA/IMMUCOR--UNSATISFIED POST-CLOSING CONDITIONS



1. Execution,  delivery and registration of a Pledge  Agreement  relative to the
stock of Immucor Portugal Lda.

2. Execution and delivery of a Pledge Agreement relative to the stock of Immucor
Belgium S.A.

3. Execution and delivery of a Pledge Agreement relative to the stock of Immucor
France EURL.

4.  Confirmation  from  Spanish  counsel  that all actions  necessary to perfect
Wachovia's lien in the stock if Immucor S.L. pursuant to the previously executed
Pledge Agreement have been taken and return of fully-executed Pledge Agreement.

5. Return of fully executed and notarized Pledge Agreement relative to the stock
of Immucor Italia s.r.l. from Italian counsel.

6.  Delivery  of  an  executed   Landlord's   Agreement  relative  to  Immucor's
headquarters in Norcross, Georgia.




<PAGE>

September 25, 2001





Mr. Edward Gallup, President, CEO
Mr. Steven C. Ramsey, Chief Financial Officer
Immucor, Inc.
3130 Gateway Drive
P.O. Box 5625
Norcross, GA. 30091-5625











Re:  Loan Modification Agreement No. 1 ( "LMA1" )


Dear Sirs:

     Section 4 ( ii ) of LMA1  refers  to May 30,  2002 as the date by which the
Junior Capital Infusion must be made, received, and applied in order for 187,500
in warrants  to be returned to Immucor.  The May 30, 2002 date should be amended
to read March 31, 2002.

     In order to reflect  the  parties'  actual  intent,  please  indicate  your
acknowledgement of this change by signing below.

                                          Sincerely,




                                          Fred Cecil
                                          Senior Vice President/GE

                                           Acknowledged by: Immucor, Inc.

                                          By:
                                                 Steven C. Ramsey
                                                 CFO
                                                 Immucor, Inc.